Chang JY - Search Results

1

Investigations of survivin: the past, present and future.

Cheung CH, Cheng L, Chang KY, Chen HH, Chang JY. Cheung CH, et al. Among authors: chang jy, chang ky. Front Biosci (Landmark Ed). 2011 Jan 1;16(3):952-61. doi: 10.2741/3728. Front Biosci (Landmark Ed). 2011. PMID: 21196211 Free article. Review.

2

Modern staging and utility of PET imaging in esophageal cancer management.

Chang KY, Chang JY, Chao J, Yen Y. Chang KY, et al. Among authors: chang jy. J Natl Compr Canc Netw. 2008 Oct;6(9):862-9. doi: 10.6004/jnccn.2008.0064. J Natl Compr Canc Netw. 2008. PMID: 18926095 Review.

3

Aurora kinase inhibitors in preclinical and clinical testing.

Cheung CH, Coumar MS, Hsieh HP, Chang JY. Cheung CH, et al. Among authors: chang jy. Expert Opin Investig Drugs. 2009 Apr;18(4):379-98. doi: 10.1517/13543780902806392. Expert Opin Investig Drugs. 2009. PMID: 19335272 Review.

4

Increasing incidence of intrahepatic cholangiocarcinoma and its relationship to chronic viral hepatitis.

Chang KY, Chang JY, Yen Y. Chang KY, et al. Among authors: chang jy. J Natl Compr Canc Netw. 2009 Apr;7(4):423-7. doi: 10.6004/jnccn.2009.0030. J Natl Compr Canc Netw. 2009. PMID: 19406042 Review.

5

Advances in Aurora kinase inhibitor patents.

Coumar MS, Cheung CH, Chang JY, Hsieh HP. Coumar MS, et al. Among authors: chang jy. Expert Opin Ther Pat. 2009 Mar;19(3):321-56. doi: 10.1517/13543770802646949. Expert Opin Ther Pat. 2009. PMID: 19441907 Review.

6

Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers.

Cheung CH, Chen HH, Kuo CC, Chang CY, Coumar MS, Hsieh HP, Chang JY. Cheung CH, et al. Among authors: chang jy, chang cy. Mol Cancer. 2009 Jul 3;8:43. doi: 10.1186/1476-4598-8-43. Mol Cancer. 2009. PMID: 19575780 Free PMC article.

7

Alpha-fetoprotein response in advanced hepatocellular carcinoma receiving cytostatic agent.

Chen LT, Shiah HS, Chao Y, Chang JY, Cheng LT, Whang-Peng J. Chen LT, et al. Among authors: chang jy. J Clin Oncol. 2009 Dec 20;27(36):e271; author reply e272. doi: 10.1200/JCO.2009.23.8311. Epub 2009 Nov 16. J Clin Oncol. 2009. PMID: 19917866 No abstract available.

8

Targeting Hsp90 with small molecule inhibitors induces the over-expression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 cancer cells.

Cheung CH, Chen HH, Cheng LT, Lyu KW, Kanwar JR, Chang JY. Cheung CH, et al. Among authors: chang jy. Mol Cancer. 2010 Apr 15;9:77. doi: 10.1186/1476-4598-9-77. Mol Cancer. 2010. PMID: 20398291 Free PMC article.

9

Cancer cells acquire mitotic drug resistance properties through beta I-tubulin mutations and alterations in the expression of beta-tubulin isotypes.

Cheung CH, Wu SY, Lee TR, Chang CY, Wu JS, Hsieh HP, Chang JY. Cheung CH, et al. Among authors: chang jy, chang cy. PLoS One. 2010 Sep 3;5(9):e12564. doi: 10.1371/journal.pone.0012564. PLoS One. 2010. PMID: 20838440 Free PMC article.

10

Antimutagenic constituents of adlay (Coix lachryma-jobi L. var. ma-yuen Stapf) with potential cancer chemopreventive activity.

Chen HH, Chiang W, Chang JY, Chien YL, Lee CK, Liu KJ, Cheng YT, Chen TF, Kuo YH, Kuo CC. Chen HH, et al. Among authors: chang jy. J Agric Food Chem. 2011 Jun 22;59(12):6444-52. doi: 10.1021/jf200539r. Epub 2011 May 17. J Agric Food Chem. 2011. PMID: 21561091

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,739 results

Search Page